Related Experiment Videos
[Non-hematologic toxicity in high-dose cytarabine therapy]
Onkologie
|February 1, 1985
Summary
High-dose cytarabine can cause non-hematologic toxicities affecting the central nervous system, eyes, skin, and gastrointestinal tract. Doses exceeding 48 g/sq m increase the risk of irreversible brain damage, but toxicity is considered acceptable for acute leukemia relapses.
Area of Science:
- Oncology
- Pharmacology
- Toxicology
Context:
- High-dose cytarabine is utilized in treating acute leukemias, particularly for relapsed or refractory cases.
- Understanding non-hematologic toxicities is crucial for managing patients undergoing intensive chemotherapy.
Purpose:
- To characterize the spectrum and dose-dependency of non-hematologic toxicities associated with high-dose cytarabine.
- To identify critical dose thresholds that elevate the risk of severe adverse events.
Summary:
- Non-hematologic toxicities commonly involve the central nervous system (cerebellar dysfunction), eyes (keratitis, conjunctivitis), skin (erythema), and gastrointestinal tract (vomiting, diarrhea).
- Toxicity is influenced by both the dosage and duration of cytarabine treatment.
- A cumulative dose of 48 g/sq m per cycle appears to be a critical threshold, significantly increasing the risk of irreversible central nervous system damage.
Impact:
- The findings help clinicians in risk-benefit assessments for high-dose cytarabine therapy.
- Establishes a potential upper limit for cytarabine dosing to mitigate severe neurological sequelae.
- Supports the continued use of high-dose cytarabine in specific acute leukemia patient populations where toxicity is deemed acceptable given the poor prognosis.